Rebecca Taub

Pres., R&D, and CMO

Rebecca Taub (Pres., R&D, and CMO) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Madrigal Pharmaceuticals, Inc. (MDGL). The largest single filing was $10.3M of MDGL (18,650 sh across 9 lots, as filed), executed Dec 10 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 6 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$21.5M

shares × price, as filed

Last traded

Mar 6

Filed Mar 6

Median ADV $194.4M across their filed names

Open performance→

Volume by month

Buys $0 Sells $49.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 6 filings

Sector per market data · by filing · past 12 months

Most traded names

MDGL

Madrigal Pharmaceuticals, Inc. MDGL · 0 buys · 11 sells 11 filings

Recent filings

MDGLSALE Madrigal Pharmaceuticals, Inc. View filing → $10.3M
29,101 sh across 9 lots
Exec Jul 16 2025
Filed Jul 18 2025 · 5:30 PM ET MDGLSALE Madrigal Pharmaceuticals, Inc. View filing → $217K
648 sh × $335.24
Exec Jan 24 2025
Filed Jan 27 2025 · 5:30 PM ET MDGLSALE Madrigal Pharmaceuticals, Inc. View filing → $462K
1,689 sh × $273.41
Exec Jan 17 2025
Filed Jan 17 2025 · 5:30 PM ET